San Diego, CA -- (SBWIRE) -- 10/17/2016 -- An investigation was announced for investors in Abbott Laboratories (NYSE:ABT) shares over potential securities laws violations by Abbott Laboratories and certain of its directors and officers.

Investors who purchased shares of Abbott Laboratories (NYSE:ABT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Abbott Laboratories (NYSE:ABT) concerning whether a series of statements by Abbott Laboratories regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 28, 2016, Abbott Laboratories announced a definitive agreement to acquire St. Jude Hospitals, Inc. ("St. Jude"), citing St. Jude's "strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management." Then on October 11, 2016, pre-market, St. Jude Medical, Inc reportedly issued a letter to physicians and patients warning that batteries on thousands of the Company's implantable defibrillators can quickly and unexpectedly deplete. St. Jude Medical, Inc reportedly stated that two people had died after their devices failed to work correctly because of the drained battery, while 47 others reported dizziness or fainting. The warning applies to devices made before May 2015, which are in use by roughly 350,000 people worldwide.

Abbott Laboratories stated that the Company still expects to close its acquisition of St. Jude by the end of this year.

Shares of Abbott Laboratories (NYSE:ABT) declined on October 14, 2106 to $40.79 per share.

Those who purchased shares of Abbott Laboratories have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com